Glecaprevir + Pibrentasvir

Generic Details

Generic Name

Glecaprevir-Pibrentasvir

Other Names

  • GLE-PIB

Drug Class

  • Direct-acting Antiviral (DAA)

Chemical Formula

Molecular Weight

Mechanism of Action

  • Inhibits HCV nonstructural protein 3/4A protease and HCV nonstructural protein 5A

Indications

  • Treatment of chronic hepatitis C virus (HCV) infection in adults

Common Dosage Forms

  • Tablet

Typical Dosage

  • The recommended dose is one tablet (glecaprevir 100 mg-pibrentasvir 40 mg) taken orally once daily with food.

Pediatric Dosage

    Geriatric Dosage

      Side Effects

      • Headache
      • Fatigue
      • Nausea
      • Insomnia
      • Irritability

      Contraindications

      • Severe hepatic impairment
      • Co-administration with certain medications like rifampin, St. John's wort, carbamazepine, and phenytoin

      Pregnancy Category

      • Unknown risk in pregnancy

      Lactation Safety

      • Not recommended during breastfeeding

      Drug Interactions

      • Moderate to strong inducers or inhibitors of CYP3A
      • P-gp inducers or inhibitors

      Overdose Symptoms

      • No specific symptoms reported

      Antidote for Overdose

      • There is no specific antidote, treatment should be symptomatic and supportive.

      Storage Conditions

      • Store at room temperature between 20-25°C (68- 77°F)

      Pharmacokinetics

      • Absorption: High oral bioavailability
      • Distribution: Protein binding is approximately 99%
      • Metabolism: Hepatic metabolism via CYP3A enzymes
      • Excretion: Primarily fecal

      Precautions

      • Monitor liver function before and during treatment

      Warnings

      • Risk of hepatitis B reactivation in patients co-infected with HCV and HBV

      Others

      • Patients may require testing for hepatitis B infection before initiating treatment.